The US Attorney's Office for the Southern District of New York is examining how Teva has marketed MS drug Copaxone and Parkinson's medication Azilect since 2006.
Movable Ink reports that 65% of Q4 emails were opened on a tablet or smartphone.
A survey of UK-based general practitioners shows industry websites are not a go-to source for information. Reps did not fare well, either.
An appeals court says J&J does not have to pay $257.7 million.
The drugmaker announced Friday that the DOJ wants documents regarding sales and marketing of Juxtapid, its drug for an ultra-rare lipid disorder.
Lobbying groups say the ad tax draft proposal could wreak havoc throughout the ad industry and its partners, such as publishers and broadcasters, if it were to go through.
The Gray Lady surveys the landscape of attention deficit disorder marketing.
The bad-ad watchdog issued an untitled letter to drugmaker Duchesnay in November.
The government division is scrutinizing marketing information for three drugs.
The marketing watchdog's untitled letter says a direct mailer failed to disclose "material facts" from the warnings and precautions section of the PI.
The agency's bad-ad warning letter calls the new violations "particularly troubling."
EyeonFDA finds that, when it comes to black-boxed drugs' marketing materials, the FDA is more likely to issue Warning Letters than untitled letters.
The drugmaker's latest financial plans could power it through mid-2015.
Subscribers will be able to use co-pay cards on Obamacare exchanges.
The drug company is ceasing US distribution and marketing the leukemia drug after the FDA said it was worried about blood clots among clinical trial patients.
Lawrence Foster's crisis management strategy has become the touchstone for reputation management. His advice is credited with saving Tylenol from being wiped from the marketplace, despite a deadly tampering crisis.
A Credit Suisse analyst notes that the company will need to make a significant impact to meet even lowered expectations. A possible fix: more sales reps behind Belviq.
Growing client demand encouraged the agency to make its HCP content capabilities official.
Despite a possible government standoff, exchanges are coming, as is a proffered rebrand; Amgen signs a university deal in China; Pakistan seeks to rein in pharma; digital marketing is on the rise, research shows
Doctors shared their information preferences with CMI/Compas, revealing ways marketers can better pace their communications to max out channels.
The company is supporting its professional pitch for the acne drug with a micro-targeted marketing strategy.
Abbott's Depakote lawsuits roll on; IMS buys mobile health firm's assets; BI shutters a chemical plant; and the healthcare reform back-and-forth continues.
Oncologists have the most restrictive access policies, a study shows for the second year in a row. But it's not impossible to book face time with these clinicians.
Pfizer settles Rapamune lawsuits; Moody's downgrades GSK; Astrazeneca pursues anemia medication; Mallinckrodt drugs gets priority review
Execs told Weber Shandwick that internal hurdles such as insufficient expertise and unclear ROI measures are really what's keeping them from the social-media mix.
Marketing partner Transcept pulled 90 sales reps and Purdue closed out the majority of its DTC outreach in March.
Jolie takes on cancer awareness role, researchers identify another adherence gap, Sanofi gets slapped for scare tactics, Teva may compete for Adcock, AbbVie R&D chief leaves
Quarterly reports show that that the weight loss category remains a cool one, but studies indicate that even the best marketing plan will have to overcome payer and pricing issues.
The first drug for morning sickness in thirty years enters the market this month.
Analysts write expanded Qsymia distribution will do little to boost sales if payers are not on board.